The number of treatments in the immuno-oncology pipeline continues to grow. Whether the treatment is CAR-T cells, checkpoint inhibitors, or adoptive T cell therapy, the mechanism of action includes T cell lysis of tumor cells.
Dr. Anne Lodge of Cellero, a Charles River company, will present data using tumor antigen-specific T cells from Cellero and commonly available tumor cell lines to demonstrate specific lysis of tumor cells using the Incucyte® Live-Cell Analysis; which offers remote monitoring of tumor cell lysis using fluorescent labels of cytotoxicity.
This webinar includes discussion on:
- The specific lysis of tumor cells
- Comparison of Annexin V and Caspase 3/7 for readout and analysis options
- The use of adherent vs suspension cells as targets
- The importance of plating density of target cells
Simply complete the form to watch this free webinar!